HALLE (SAALE), Germany, 15 October 2018 – The management board of Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to […]
HALLE (SAALE), Germany, 09 October, 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
HALLE (SAALE), Germany, October 5th, 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announced today […]
HALLE (SAALE), Germany, 04 September, 2018: Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today […]
HALLE (SAALE), Germany, 30 August 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]
HALLE (SAALE), Germany, 23 August 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its […]
All proposed resolutions approved with large majority HALLE (SAALE), Germany, 22 June 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel […]
HALLE (SAALE), Germany, 29 May 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
HALLE (SAALE), Germany, 25 May 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces today […]